Physicochemical Properties
| Molecular Formula | C89H137N23O25S |
| Molecular Weight | 1961.24419951439 |
| Exact Mass | 1959.987 |
| CAS # | 887255-16-5 |
| Related CAS # | LQVTDSGLYRCVIYHPP TFA |
| PubChem CID | 16156342 |
| Appearance | White to off-white solid powder |
| LogP | -3.3 |
| Hydrogen Bond Donor Count | 27 |
| Hydrogen Bond Acceptor Count | 29 |
| Rotatable Bond Count | 58 |
| Heavy Atom Count | 138 |
| Complexity | 4160 |
| Defined Atom Stereocenter Count | 18 |
| SMILES | C(N1CCC[C@H]1C(=O)O)([C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@]([H])([C@@H](C)CC)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H](N)CC(C)C)CC1C=CC(O)=CC=1)CC1C=CC(O)=CC=1)CC1NC=NC=1)=O |
| InChi Key | AGSGAKFOVYNZSG-NOULYIDWSA-N |
| InChi Code | InChI=1S/C89H137N23O25S/c1-12-47(10)71(84(132)102-59(35-50-21-25-53(116)26-22-50)79(127)104-61(36-51-38-94-42-97-51)86(134)111-30-14-17-64(111)87(135)112-31-15-18-65(112)88(136)137)109-82(130)69(45(6)7)108-81(129)63(41-138)106-75(123)55(16-13-29-95-89(92)93)100-78(126)58(34-49-19-23-52(115)24-20-49)101-77(125)57(33-44(4)5)98-67(118)39-96-74(122)62(40-113)105-80(128)60(37-68(119)120)103-85(133)72(48(11)114)110-83(131)70(46(8)9)107-76(124)56(27-28-66(91)117)99-73(121)54(90)32-43(2)3/h19-26,38,42-48,54-65,69-72,113-116,138H,12-18,27-37,39-41,90H2,1-11H3,(H2,91,117)(H,94,97)(H,96,122)(H,98,118)(H,99,121)(H,100,126)(H,101,125)(H,102,132)(H,103,133)(H,104,127)(H,105,128)(H,106,123)(H,107,124)(H,108,129)(H,109,130)(H,110,131)(H,119,120)(H,136,137)(H4,92,93,95)/t47-,48+,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,69-,70-,71-,72-/m0/s1 |
| Chemical Name | (2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | LQVTDSGLYRCVIYHPP (LP17) (1 or 10 μM; 24 hours) dramatically lowers IL-1β and IL-1β in small stellate cell oxygen proliferation (OGD) and greatly lowers the mRNA levels of proinflammatory cytokines and chemokines following reoxygenation. In response to astrocyte SYK, LQVTDSGLYRCVIYHPP (LP17) (10 μM; 24 hours) acts [1]. |
| ln Vivo | LQVTDSGLYRCVIYHPP (LP17) attenuates simulator-induced infarcted neurons and neuronal damage when administered intravenously once day for three days at a dose of 0.5 or 1 mg/kg [1]. |
| Cell Assay |
RT-PCR[1] Cell Types: Primary microglia Tested Concentrations: 1 Extracellular protein level model of IL-18[1]. or 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: The mRNA levels of NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, iNOS, MCP-1, CXCL-1 and CXCL-2 were diminished after reoxygenation. Western Blot Analysis[1] Cell Types: Primary Microglia Tested Concentrations: 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: CARD9, p-p65 and NLRP3, ASC, cleaved caspase-deficient in CARD9/NF-κB signaling The blood/reperfusion-induced increase in 1, mature IL-1β and mature IL-18 in NLRP3/caspase-1 signaling is inhibited in a microglia model of oxygenated glucose hypoxia (OGD). |
| Animal Protocol |
Animal/Disease Models: Adult male C57BL/6J mice (20-25 g), middle cerebral artery occlusion (MCAO)-induced mouse cerebral ischemia/reperfusion (I/R) model [1] Doses: 0.5 mg/kg or 1 mg/kg Route of Administration: intranasal administration, one time/day, MCAO for 3 days. Experimental Results: 1 mg/kg dose can eliminate the ischemia-induced increase in TREM-1. 1 mg/kg can Dramatically reduce infarct volume by 27.3% and induce a significant decrease in TUNEL-positive cells and FJC-positive neurons. Rescue neurological deficits and cognitive dysfunction in MCAO mice. Inhibits microglial M1 polarization and neutrophil infiltration. |
| References |
[1]. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke. Cell Death Dis. 2019 Jul 19;10(8):555. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~12.75 mM) H2O : ~5 mg/mL (~2.55 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5099 mL | 2.5494 mL | 5.0988 mL | |
| 5 mM | 0.1020 mL | 0.5099 mL | 1.0198 mL | |
| 10 mM | 0.0510 mL | 0.2549 mL | 0.5099 mL |